TrialPloS one2021

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

Martin Demarchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.